Inter and Intratumour heterogeneity: a barrier to individualised medical therapy in renal cell carcinoma?

Gespeichert in:

Autor*in:	Rosalie eFisher [verfasserIn] James eLarkin [verfasserIn] Charles eSwanton [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2012

Schlagwörter:	Drug Resistance biomarker Intra-tumour heterogeneity Inter-tumour heterogeneity Personalised medicine Tumour sampling bias

Übergeordnetes Werk:	In: Frontiers in Oncology - Frontiers Media S.A., 2012, 2(2012)
Übergeordnetes Werk:	volume:2 ; year:2012

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3389/fonc.2012.00049

Katalog-ID:	DOAJ068649215

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ068649215
003	DE-627
005	20230309080220.0
007	cr uuu---uuuuu
008	230228s2012 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3389/fonc.2012.00049 \|2 doi
035			\|a (DE-627)DOAJ068649215
035			\|a (DE-599)DOAJe48d17a378b646e4a2cae74f214c5250
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC254-282
100	0		\|a Rosalie eFisher \|e verfasserin \|4 aut
245	1	0	\|a Inter and Intratumour heterogeneity: a barrier to individualised medical therapy in renal cell carcinoma?
264		1	\|c 2012
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
650		4	\|a Drug Resistance
650		4	\|a biomarker
650		4	\|a Intra-tumour heterogeneity
650		4	\|a Inter-tumour heterogeneity
650		4	\|a Personalised medicine
650		4	\|a Tumour sampling bias
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a James eLarkin \|e verfasserin \|4 aut
700	0		\|a Charles eSwanton \|e verfasserin \|4 aut
773	0	8	\|i In \|t Frontiers in Oncology \|d Frontiers Media S.A., 2012 \|g 2(2012) \|w (DE-627)684965518 \|w (DE-600)2649216-7 \|x 2234943X \|7 nnns
773	1	8	\|g volume:2 \|g year:2012
856	4	0	\|u https://doi.org/10.3389/fonc.2012.00049 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/e48d17a378b646e4a2cae74f214c5250 \|z kostenfrei
856	4	0	\|u http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00049/full \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2234-943X \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 2 \|j 2012

Indexfelder

author_variant	r e re j e je c e ce
matchkey_str	article:2234943X:2012----::neadnrtmuhtrgniybrironiiulsdeiate
hierarchy_sort_str	2012
callnumber-subject-code	RC
publishDate	2012
allfields	10.3389/fonc.2012.00049 doi (DE-627)DOAJ068649215 (DE-599)DOAJe48d17a378b646e4a2cae74f214c5250 DE-627 ger DE-627 rakwb eng RC254-282 Rosalie eFisher verfasserin aut Inter and Intratumour heterogeneity: a barrier to individualised medical therapy in renal cell carcinoma? 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Drug Resistance biomarker Intra-tumour heterogeneity Inter-tumour heterogeneity Personalised medicine Tumour sampling bias Neoplasms. Tumors. Oncology. Including cancer and carcinogens James eLarkin verfasserin aut Charles eSwanton verfasserin aut In Frontiers in Oncology Frontiers Media S.A., 2012 2(2012) (DE-627)684965518 (DE-600)2649216-7 2234943X nnns volume:2 year:2012 https://doi.org/10.3389/fonc.2012.00049 kostenfrei https://doaj.org/article/e48d17a378b646e4a2cae74f214c5250 kostenfrei http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00049/full kostenfrei https://doaj.org/toc/2234-943X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2012
spelling	10.3389/fonc.2012.00049 doi (DE-627)DOAJ068649215 (DE-599)DOAJe48d17a378b646e4a2cae74f214c5250 DE-627 ger DE-627 rakwb eng RC254-282 Rosalie eFisher verfasserin aut Inter and Intratumour heterogeneity: a barrier to individualised medical therapy in renal cell carcinoma? 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Drug Resistance biomarker Intra-tumour heterogeneity Inter-tumour heterogeneity Personalised medicine Tumour sampling bias Neoplasms. Tumors. Oncology. Including cancer and carcinogens James eLarkin verfasserin aut Charles eSwanton verfasserin aut In Frontiers in Oncology Frontiers Media S.A., 2012 2(2012) (DE-627)684965518 (DE-600)2649216-7 2234943X nnns volume:2 year:2012 https://doi.org/10.3389/fonc.2012.00049 kostenfrei https://doaj.org/article/e48d17a378b646e4a2cae74f214c5250 kostenfrei http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00049/full kostenfrei https://doaj.org/toc/2234-943X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2012
allfields_unstemmed	10.3389/fonc.2012.00049 doi (DE-627)DOAJ068649215 (DE-599)DOAJe48d17a378b646e4a2cae74f214c5250 DE-627 ger DE-627 rakwb eng RC254-282 Rosalie eFisher verfasserin aut Inter and Intratumour heterogeneity: a barrier to individualised medical therapy in renal cell carcinoma? 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Drug Resistance biomarker Intra-tumour heterogeneity Inter-tumour heterogeneity Personalised medicine Tumour sampling bias Neoplasms. Tumors. Oncology. Including cancer and carcinogens James eLarkin verfasserin aut Charles eSwanton verfasserin aut In Frontiers in Oncology Frontiers Media S.A., 2012 2(2012) (DE-627)684965518 (DE-600)2649216-7 2234943X nnns volume:2 year:2012 https://doi.org/10.3389/fonc.2012.00049 kostenfrei https://doaj.org/article/e48d17a378b646e4a2cae74f214c5250 kostenfrei http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00049/full kostenfrei https://doaj.org/toc/2234-943X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2012
allfieldsGer	10.3389/fonc.2012.00049 doi (DE-627)DOAJ068649215 (DE-599)DOAJe48d17a378b646e4a2cae74f214c5250 DE-627 ger DE-627 rakwb eng RC254-282 Rosalie eFisher verfasserin aut Inter and Intratumour heterogeneity: a barrier to individualised medical therapy in renal cell carcinoma? 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Drug Resistance biomarker Intra-tumour heterogeneity Inter-tumour heterogeneity Personalised medicine Tumour sampling bias Neoplasms. Tumors. Oncology. Including cancer and carcinogens James eLarkin verfasserin aut Charles eSwanton verfasserin aut In Frontiers in Oncology Frontiers Media S.A., 2012 2(2012) (DE-627)684965518 (DE-600)2649216-7 2234943X nnns volume:2 year:2012 https://doi.org/10.3389/fonc.2012.00049 kostenfrei https://doaj.org/article/e48d17a378b646e4a2cae74f214c5250 kostenfrei http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00049/full kostenfrei https://doaj.org/toc/2234-943X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2012
allfieldsSound	10.3389/fonc.2012.00049 doi (DE-627)DOAJ068649215 (DE-599)DOAJe48d17a378b646e4a2cae74f214c5250 DE-627 ger DE-627 rakwb eng RC254-282 Rosalie eFisher verfasserin aut Inter and Intratumour heterogeneity: a barrier to individualised medical therapy in renal cell carcinoma? 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Drug Resistance biomarker Intra-tumour heterogeneity Inter-tumour heterogeneity Personalised medicine Tumour sampling bias Neoplasms. Tumors. Oncology. Including cancer and carcinogens James eLarkin verfasserin aut Charles eSwanton verfasserin aut In Frontiers in Oncology Frontiers Media S.A., 2012 2(2012) (DE-627)684965518 (DE-600)2649216-7 2234943X nnns volume:2 year:2012 https://doi.org/10.3389/fonc.2012.00049 kostenfrei https://doaj.org/article/e48d17a378b646e4a2cae74f214c5250 kostenfrei http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00049/full kostenfrei https://doaj.org/toc/2234-943X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2012
language	English
source	In Frontiers in Oncology 2(2012) volume:2 year:2012
sourceStr	In Frontiers in Oncology 2(2012) volume:2 year:2012
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Drug Resistance biomarker Intra-tumour heterogeneity Inter-tumour heterogeneity Personalised medicine Tumour sampling bias Neoplasms. Tumors. Oncology. Including cancer and carcinogens
isfreeaccess_bool	true
container_title	Frontiers in Oncology
authorswithroles_txt_mv	Rosalie eFisher @@aut@@ James eLarkin @@aut@@ Charles eSwanton @@aut@@
publishDateDaySort_date	2012-01-01T00:00:00Z
hierarchy_top_id	684965518
id	DOAJ068649215
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ068649215</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309080220.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2012 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3389/fonc.2012.00049</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ068649215</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJe48d17a378b646e4a2cae74f214c5250</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Rosalie eFisher</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Inter and Intratumour heterogeneity: a barrier to individualised medical therapy in renal cell carcinoma?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2012</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Resistance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">biomarker</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Intra-tumour heterogeneity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Inter-tumour heterogeneity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Personalised medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tumour sampling bias</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">James eLarkin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Charles eSwanton</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Frontiers in Oncology</subfield><subfield code="d">Frontiers Media S.A., 2012</subfield><subfield code="g">2(2012)</subfield><subfield code="w">(DE-627)684965518</subfield><subfield code="w">(DE-600)2649216-7</subfield><subfield code="x">2234943X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:2012</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3389/fonc.2012.00049</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/e48d17a378b646e4a2cae74f214c5250</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00049/full</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2234-943X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">2012</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Rosalie eFisher
spellingShingle	Rosalie eFisher misc RC254-282 misc Drug Resistance misc biomarker misc Intra-tumour heterogeneity misc Inter-tumour heterogeneity misc Personalised medicine misc Tumour sampling bias misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Inter and Intratumour heterogeneity: a barrier to individualised medical therapy in renal cell carcinoma?
authorStr	Rosalie eFisher
ppnlink_with_tag_str_mv	@@773@@(DE-627)684965518
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC254-282
illustrated	Not Illustrated
issn	2234943X
topic_title	RC254-282 Inter and Intratumour heterogeneity: a barrier to individualised medical therapy in renal cell carcinoma? Drug Resistance biomarker Intra-tumour heterogeneity Inter-tumour heterogeneity Personalised medicine Tumour sampling bias
topic	misc RC254-282 misc Drug Resistance misc biomarker misc Intra-tumour heterogeneity misc Inter-tumour heterogeneity misc Personalised medicine misc Tumour sampling bias misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_unstemmed	misc RC254-282 misc Drug Resistance misc biomarker misc Intra-tumour heterogeneity misc Inter-tumour heterogeneity misc Personalised medicine misc Tumour sampling bias misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_browse	misc RC254-282 misc Drug Resistance misc biomarker misc Intra-tumour heterogeneity misc Inter-tumour heterogeneity misc Personalised medicine misc Tumour sampling bias misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Frontiers in Oncology
hierarchy_parent_id	684965518
hierarchy_top_title	Frontiers in Oncology
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)684965518 (DE-600)2649216-7
title	Inter and Intratumour heterogeneity: a barrier to individualised medical therapy in renal cell carcinoma?
ctrlnum	(DE-627)DOAJ068649215 (DE-599)DOAJe48d17a378b646e4a2cae74f214c5250
title_full	Inter and Intratumour heterogeneity: a barrier to individualised medical therapy in renal cell carcinoma?
author_sort	Rosalie eFisher
journal	Frontiers in Oncology
journalStr	Frontiers in Oncology
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2012
contenttype_str_mv	txt
author_browse	Rosalie eFisher James eLarkin Charles eSwanton
container_volume	2
class	RC254-282
format_se	Elektronische Aufsätze
author-letter	Rosalie eFisher
doi_str_mv	10.3389/fonc.2012.00049
author2-role	verfasserin
title_sort	inter and intratumour heterogeneity: a barrier to individualised medical therapy in renal cell carcinoma?
callnumber	RC254-282
title_auth	Inter and Intratumour heterogeneity: a barrier to individualised medical therapy in renal cell carcinoma?
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
title_short	Inter and Intratumour heterogeneity: a barrier to individualised medical therapy in renal cell carcinoma?
url	https://doi.org/10.3389/fonc.2012.00049 https://doaj.org/article/e48d17a378b646e4a2cae74f214c5250 http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00049/full https://doaj.org/toc/2234-943X
remote_bool	true
author2	James eLarkin Charles eSwanton
author2Str	James eLarkin Charles eSwanton
ppnlink	684965518
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3389/fonc.2012.00049
callnumber-a	RC254-282
up_date	2024-07-03T18:59:07.941Z
_version_	1803585478139576321
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ068649215</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309080220.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2012 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3389/fonc.2012.00049</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ068649215</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJe48d17a378b646e4a2cae74f214c5250</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Rosalie eFisher</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Inter and Intratumour heterogeneity: a barrier to individualised medical therapy in renal cell carcinoma?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2012</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Resistance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">biomarker</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Intra-tumour heterogeneity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Inter-tumour heterogeneity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Personalised medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tumour sampling bias</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">James eLarkin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Charles eSwanton</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Frontiers in Oncology</subfield><subfield code="d">Frontiers Media S.A., 2012</subfield><subfield code="g">2(2012)</subfield><subfield code="w">(DE-627)684965518</subfield><subfield code="w">(DE-600)2649216-7</subfield><subfield code="x">2234943X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:2012</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3389/fonc.2012.00049</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/e48d17a378b646e4a2cae74f214c5250</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00049/full</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2234-943X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">2012</subfield></datafield></record></collection>
score	7.39985

Nicht das Richtige dabei?

Schreiben Sie uns!

Inter and Intratumour heterogeneity: a barrier to individualised medical therapy in renal cell carcinoma?

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?